According to the lawsuits, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- The study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis;
- The data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan;
- These issues presented a substantial concern regarding the viability of ChemoCentryx’s New Drug Application (“NDA”) for avacopan for the treatment of ANCA-associated vasculitis; and
- As a result of the foregoing, defendants’ public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.